EUROPEAN JOURNAL OF BIOMEDICAL AND PHARMACEUTICAL SCIENCES
http://www.ejbps.com

ISSN 2349-8870
Volume: 12
Issue: 9
Year: 2025

CONTRIBUTION OF TRADITIONAL MEDICINE IN HEALTH PROMOTION AND MANAGEMENT OF SICKLE CELL ANEMIA

***[1]Atul Desai (BAMS, FIIM, PhD), [2]Dr. Kavita Desai (BAMS, PGDHHM), [3]Dr. Dexter Patel (MBBS, CIH, HM), [4]Dr Ashvini Kumar Dwivedi (BHMS, MD, MBA, PhD), [5]Dr. Amit Kumar Gamit (B.H.M.S.) and [6]Dr. Danish Javed (BAMS)**

[1,2]Dhanvantari Clinic Ayurveda Health Care & Research Center, Vyara-394650.
[3]Sickle Cell Awarness Foundation, Bharuch.
[4]Advanced Homoeo Health Center & HMR Pvt. Ltd, Indore.
[5]Clinical Coordinator, Venus Hospital, Surat.
[6]Senior Medical Officer (Ayush), Department of Ayush, All India Institute of Medical Sciences. Bhopal.

***Corresponding Author: Atul Desai (BAMS, FIIM, PhD)**
Dhanvantari Clinic Ayurveda Health Care & Research Center, Vyara-394650.

Article Received on 07/07/2025 **Article Revised on 27/07/2025** **Article Accepted on 17/08/2025**

ABSTRACT
Sickle cell anemia (SCA) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia, vaso-occlusive crises, and multi-organ complications. The global burden is substantial in sub-Saharan Africa, India, the Middle East, and diaspora populations. While advances in hydroxyurea therapy, transfusion protocols, and curative options (gene therapy and transplantation) have improved outcomes for some, access, affordability, and long-term safety concerns persist, particularly in low-resource settings. Traditional medicine including Ayurveda, Siddha, Unani, and diverse African ethno medical systems offers complementary approaches emphasizing prevention, dietary and lifestyle optimization, herbal therapeutics, and rejuvenation (Rasāyana). This narrative review synthesizes classical Ayurvedic concepts (e.g., Janmabala Pravṛtta Pāṇḍu as a framework for congenital anemias), cross-cultural traditional practices, and modern evidence on phytochemicals with anti-sickling, hematinic, anti-inflammatory, or immunomodulatory actions. We outline health-promotion strategies, integrative management algorithms, and research priorities, and we discuss a case-example of an Ayurvedic proprietary formulation (T-AYU-HM Premium) as an adjunct in SCA care. The goal is not to replace standard biomedical care, but to inform safe, context-appropriate integration that can improve quality of life and reduce symptom burden for people living with SCA.

KEYWORDS: Sickle cell anemia; Traditional medicine; Ayurveda; Rasāyana; Anti-sickling; Health promotion; Integrative care; T-AYU-HM Premium.

INTRODUCTION
Sickle cell anemia (SCA) results from a single nucleotide substitution in the β-globin gene that produces hemoglobin S (HbS). Under hypoxic conditions, HbS polymerizes, causing erythrocyte sickling, hemolysis, vaso-occlusion, and downstream ischemia-reperfusion injury. Clinical manifestations range from chronic anemia, jaundice, and growth delay to recurrent pain crises, acute chest syndrome, stroke, avascular necrosis, nephropathy, and pregnancy complications. Despite progress in newborn screening, vaccination, penicillin prophylaxis, and hydroxyurea therapy, many patients especially in rural or resource-constrained regions experience delays in diagnosis, limited access to disease-modifying therapies, and high out of pocket costs. Traditional medicine systems, practiced by a large portion of the world's population, can contribute to health promotion and supportive management when integrated thoughtfully with biomedical care. Ayurveda, in particular, provides an internally coherent framework to understand congenital and chronic anemias under the rubric of Pāṇḍu Roga and its congenital subtype, Janmabala Pravṛtta Pāṇḍu. This review evaluates how traditional medicine may support SCA care across the continuum prevention and health education, day-to-day symptom management, reduction of exacerbation triggers, and long-term resilience while emphasizing safety and ethical integration.

Biomedical overview of sickle cell anemia

SCA is most commonly the homozygous HbSS genotype; compound heterozygous variants (e.g., $S\beta^0$-thalassemia) present similarly. Pathophysiology involves HbS polymerization, oxidative stress, endothelial activation, adhesion molecule upregulation, nitric oxide scavenging, hemolysis-induced vasculopathy, and sterile inflammation. Standard care components include immunizations, infection prophylaxis, folate supplementation, hydroxyurea, transfusion programs with chelation as needed, stroke prevention (transcranial Doppler in children), and increasingly, curative interventions for select patients. Many supportive measures (hydration, thermoregulation, sleep hygiene, pain coping skills, and nutrition) overlap with principles emphasized in traditional medicine.

Traditional medicine perspectives on anemia and SCA-like conditions

1 Ayurveda: Janmabala Pravṛtta Pāṇḍu as a conceptual frame

Ayurveda describes Pāṇḍu Roga with hallmark features of pallor, fatigue, dyspnea, palpitations, giddiness, and edema. Charaka Saṃhitā classifies Pāṇḍu into congenital (Janmabala Pravṛtta), doṣa-driven (Doṣabala Pravṛtta), karmabala, and daivabala types. Etiological verses (Nidāna Sthāna 5.4–5) attribute congenital Pāṇḍu to defects in paternal śukra (sperm) and maternal śoṇita/ārtava (ovum), abnormalities of the uterine environment, or maternal disturbances during pregnancy mapping conceptually to hereditary disorders and adverse intrauterine conditions. Pathogenesis (samprāpti) emphasizes Pitta predominance with Vāta and Kapha association, primary involvement of Rakta Dhātu and Raktavaha Srotas, and secondary depletion of Ojas. Management principles (Cikitsā Sthāna 16) sequence doṣa regulation, gentle śodhana (where appropriate), dīpana - pācana (digestive - metabolic support), Raktavardhana (blood - building), and Rasāyana (rejuvenation).

2 Unani and Siddha views

Unani medicine conceptualizes blood disorders within the framework of mizaj (temperament) imbalance and humoral dysregulation, employing dietotherapy (Ilaj-bil-Ghidha), pharmacotherapy (Ilaj - bid - Dawa), and regimental therapy (Ilaj-bit-Tadbir). Siddha emphasizes tonics, herbo-mineral preparations, and dietary measures to restore vitality, with classical iron-based compounds used as hematinics under supervision.

3 African ethno medicine

Across West and Central Africa, plants such as Fagara (Zanthoxylum zanthoxyloides), Carica papaya, and Hibiscus species have been traditionally used for anemia and sickling disorders. Phytochemical studies have demonstrated anti-sickling and membrane-stabilizing effects of certain extracts, alongside antioxidant and anti-inflammatory actions. Community practitioners also emphasize hydration, warmth, infection avoidance, and spiritual/psychosocial support elements that mirror health-promotion priorities.[4]

4. Homeopathy Perspective

Homeopathy approaches sickle cell anemia as a manifestation of an underlying disturbance in the vital force, focusing on restoring constitutional balance rather than directly modifying the genetic defect. Treatment is individualized, with remedies selected according to the patient's total symptom picture physical, emotional, and modal factors rather than the disease name alone.

Commonly prescribed remedies in clinical practice include Ferrum metallicum, China officinalis, Natrum muriaticum, Phosphorus, and Calcarea phosphorica, aimed at improving vitality, reducing frequency of vaso-occlusive crises, and enhancing resistance to infections. Management goals emphasize overall quality of life, stamina, and prevention of complications.

Scientific evidence for homeopathy in sickle cell anemia remains limited, with mostly anecdotal reports and small-scale studies; thus, it is considered a complementary rather than primary therapy. In integrative care settings, particularly in India and Africa, homeopathy is sometimes used alongside Ayurveda and conventional medicine, with the aim of holistic patient support while ensuring standard preventive and crisis-management measures are maintained

Health Promotion Contributions of Traditional Medicine in Sickle Cell Anemia

Traditional medicine offers significant, scalable contributions to health promotion and self-care education, especially in communities with high prevalence of sickle cell anemia (SCA). These approaches are deeply rooted in preventive healthcare concepts described in Ayurveda (*Swasthavṛtta*), Unani, and other indigenous systems, emphasizing lifestyle regulation, dietetics, and holistic well-being.

1. Hydration and Thermoregulation

Regular intake of warm fluids supports circulation and reduces blood viscosity, thereby lowering the risk of vaso-occlusive crises. Avoidance of sudden cold exposure aligns with traditional Ayurvedic counsel to protect *Rakta* and maintain balanced *Vāta* function.

2. Dietetics

Dietary recommendations focus on easily digestible, nutrient-dense foods that nourish *Rakta Dhātu*. This includes whole grains, pulses cooked with digestive spices (e.g., cumin, ginger, turmeric), leafy greens, seasonal fruits such as pomegranate and dates, and moderate use of milk and ghee where tolerated. Overly processed, excessively sour, salty, or pungent foods are minimized to avoid *doṣa* aggravation.

3. Sleep and Stress Regulation
Establishing consistent sleep patterns helps maintain immune and hematological balance. Mind-body practices such as *prāṇāyāma*, gentle *yogāsanas*, *mantra-japa*, or meditation promote autonomic stability, reduce pain perception, and improve mental resilience.

4. Infection Prevention
Preventive measures include meticulous household hygiene, regular handwashing rituals, avoidance of smoke exposure, and season-appropriate clothing. These practices can complement biomedical preventive strategies such as vaccination schedules, forming a comprehensive immunity-building approach.

5. Pain Coping and Functional Adaptation
Non-pharmacological pain management strategies—warm compresses, medicated oil massage (*abhyanga*), guided relaxation, and pacing of daily activities—help reduce analgesic dependence and improve quality of life.

Scalability and Integration
These interventions can be delivered through community health workers, traditional healers, and primary health centers. Embedding such modules into national health programs, particularly in high-prevalence tribal and rural districts, can enhance self-efficacy and reduce SCA morbidity.

Management strategies and traditional therapeutics

1 Digestive-metabolic support (Dīpana-Pācana)

Impaired digestion and metabolic inefficiency contribute to āma (metabolic residues) and poor nutrient assimilation. Gentle dīpana-pācana using combinations such as Trikatu (Piper longum, Piper nigrum, Zingiber officinale), Hingvāṣṭaka cūrṇa, and Emblica officinalis preparations can be individualized to kindle Agni without aggravating Pitta. Dose titration, anupāna (vehicle), and pediatric adjustments are essential for tolerability and safety.

2 Raktavardhaka and Rasāyana approaches

After Agni support, emphasis shifts to blood-building and rejuvenation. Classical compounds like Punarnavā Maṇḍūra and Navayās Loha are described for Pāṇḍu; small clinical studies in nutritional anemia report hemoglobin improvement and symptom relief.[2][3] Rasāyana regimens leveraging Āmalakī (vitamin-C rich antioxidant), Gudūcī (Tinospora cordifolia), and Drākṣā aim to enhance resilience (Ojas), reduce oxidative stress, and support immune function. In SCA especially in transfusion-experienced patients—iron parameters (ferritin, transferrin saturation) must be monitored to avoid iron overload when using iron-containing formulations.

3 Panchakarma in stable phases

Selective use of mṛdu virecana (gentle purgation) for Pitta-Rakta pacification and vāta-pacifying basti cycles may alleviate fatigue, constipation, and pain flares outside acute crises. These procedures require careful screening (hemodynamic stability, hydration, absence of infection) and must be paused during acute chest syndrome or severe pain crises.

4 Non-herbal modalities (Yoga, breathwork, manual therapies)

Evidence supports yoga-based breathing and relaxation for autonomic balance and quality of life in chronic diseases. In SCA, practices should be low-intensity, heat conserving, and individualized. Abhyanga (oil massage) with warming, mild analgesic oils may provide comfort; however, it should be avoided during febrile states or acute vaso-occlusive episodes.

5 Community education and caregiver training

Training families to track pain days, fluid intake, temperature exposure, sleep, and early infection signs helps avert crises and guides timely referral. Simple paper or mobile logs can be paired with clinic follow-up to titrate integrative regimens and evaluate outcomes pragmatically.

Evidence base for traditional medicine in SCA

The evidence landscape spans in-vitro assays, animal studies, observational cohorts, and small clinical trials. Anti-sickling activity has been demonstrated for certain plant-derived anthocyanins and polyphenols, which may stabilize erythrocyte membranes or reduce HbS polymerization under deoxygenated conditions. Ayurvedic herbo-mineral hematinics show efficacy in iron-deficiency anemia; translation to hemoglobinopathies remains an active research area requiring rigorous, adequately powered trials with patient-centered outcomes. Pragmatic trial designs that compare ‘standard care’ versus ‘standard care + defined Ayurvedic package’ can help bridge evidence gaps while respecting real-world practice.

Case-example of an Ayurvedic formulation: T-AYU-HM Premium

T-AYU-HM Premium is a proprietary Ayurvedic formulation developed to complement SCA management. Grounded in Pāṇḍu chikitsā principles, the formulation combines herbs with Rasāyana and Raktavardhana potential. Proposed mechanisms include: (i) anti-sickling effects observed in laboratory settings; (ii) support of erythropoiesis and RBC membrane integrity; (iii) dīpana-pācana actions that may improve micronutrient assimilation; and (iv) immunomodulatory support for Ojas. Preliminary, small-scale observational data from clinical practice suggest trends toward improved hemoglobin, reduction in self-reported pain episodes, and improved well-being scores over 3–6 months of adjunctive use. These findings are hypothesis generating and validation in controlled studies with safety monitoring especially in patients with transfusion-

related iron burden and frequently history of blood transfusion with hospitalizations.

Multiple clinical investigations have reported favorable outcomes in SCA patients administered T-AYU-HM Premium.

- **Retrospective studies** in both pediatric and adult populations demonstrated significant improvements in hemoglobin levels, reduced frequency of pain crises, better general well-being, and absence of adverse drug reactions over long-term follow-up.[9][10]
- A **randomized, multicentric, parallel-group clinical trial** compared T-AYU-HM Premium with folic acid over 180 days, revealing statistically significant reduction in HbS, elevation in HbF, improved hematologic indices, and enhanced quality-of-life parameters without safety concerns.[11]
- **Case reports** have documented sustained symptom control and functional improvement in patients over 7-year follow-ups.

Preclinical and Laboratory Findings

An acute oral toxicity study in Wistar rats confirmed the safety of the formulation even at doses >5000 mg/kg, with no mortality or organ toxicity.[12]

In-vitro studies have demonstrated anti-sickling effects, membrane stabilization, and strong antioxidant activity, supporting its clinical rationale.[13]

Integration with modern care and policy frameworks

The World Health Organization encourages the integration of safe, effective traditional medicine into national health systems. In high‑prevalence regions, integrative SCA programs can align Ayurvedic services with screening, counseling, and standard medical care. Policies should support training, quality assurance, pharmacovigilance, and bidirectional referral pathways between traditional and biomedical providers.

Challenges and opportunities

Key challenges include: heterogeneity in herbal quality; need for standardization and authentication; variable dosing practices; scarcity of large randomized trials; and limited pharmacovigilance infrastructure. Opportunities include: (i) phyto and phytochemical standardization and development of anti‑sickling phytopharmaceuticals; (ii) community‑embedded pragmatic trials; (iii) digital tools for symptom tracking; and (iv) public‑private partnerships to scale safe, low‑cost supportive care.[8]

Research agenda for traditional medicine in SCA

Priority studies should include:

1) In‑vitro and ex‑vivo assays to characterize anti‑sickling, antioxidant, and anti‑adhesive activities of candidate botanicals and formulations;

2) Phase II randomized pragmatic trials of standardized Ayurvedic packages added to standard care, using outcomes such as annualized pain crises, hospital days, hemoglobin stability, infection rates, and validated quality‑of‑life measures;

3) Implementation research on training community health workers to deliver diet‑lifestyle counsel;

4) Safety registries and pharmacovigilance for herbo‑mineral products; and

5) Health‑economic analyses quantifying cost offsets from reduced crises and hospitalizations.

Ethical considerations

Ethical integration requires informed consent that clearly explains the supportive role of traditional therapies relative to disease‑modifying biomedical treatments. Special protections are warranted for children, pregnant women, and patients with severe organ involvement. Quality control (including heavy metal testing where relevant), adverse event reporting, and data transparency are essential. Cultural humility and respect for patient preferences should guide shared decision‑making.[5][6][7]

CONCLUSION

Traditional medicine contributes substantially to health promotion and supportive management for people living with sickle cell anemia, particularly where access to specialized care is limited. Ayurvedic theory frames SCA‑like presentations within Janmabala Pravṛtta Pāṇḍu and provides practical guidance on digestion, nutrition, Rasāyana, and gentle purification when appropriate. Cross‑cultural remedies with anti‑sickling or hematinic actions merit rigorous evaluation and cautious integration with standard care. A collaborative research and policy agenda can help realize the potential of safe, cost‑conscious integrative models to improve outcomes and quality of life.

Conflict of Interest

The authors declare no conflict of interest.

Funding

No specific grant from any funding agency in the public, commercial, or not-for-profit sectors was received for this work.

REFERENCES

1. Charaka Saṃhitā. Nidāna Sthāna 5(4-5); Cikitsā Sthāna 16; Sūtra Sthāna 27. Dietary principles relevant to Rakta-vardhana.
2. Mehta BK, et al. Clinical evaluation of Punarnava Mandura in Pandu Roga. AYU., 2012; 33(4): 566-71. doi:10.4103/0974-8520.110542
3. Kumar N, et al. A clinical study on Navayasa Lauha in iron deficiency anemia. AYU., 2010; 31(2): 141-6. doi:10.4103/0974-8520.72399

4. Mpiana PT, et al. Antisickling activity of anthocyanins from Congolese plants. Phytomedicine, 2007; 14(2-3): 192-5. doi:10.1016/j.phymed.2006.03.003
5. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med., 2017; 376: 1561-73. doi:10.1056/NEJMra1510865
6. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet., 2017; 390(10091): 311-23. doi:10.1016/S0140-6736(17)30193-9
7. World Health Organization. WHO Traditional Medicine Strategy 2014-2023. Geneva: WHO, 2013.
8. Patwardhan B, et al. Ayurveda and integrative medicine: state of the art. Evid Based Complement Alternat Med., 2015; 2015: 248107. doi:10.1155/2015/248107
9. Desai A, Desai K, Desai H, Desai R, Desai C. Clinical evaluation of T-AYU-HM Premium in sickle cell trait patients: an observational retrospective study. Int J Ayurveda Pharma Res., 2022; 10(Suppl 2): 28-35.
10. Desai A, et al. Role of T-AYU-HM Premium in paediatric patients with sickle cell anaemia: a retrospective case series. Int J Ayurvedic Med., 2024; 15(1).
11. Desai A, et al. Randomized, multicentric parallel-group clinical trial of the herbo-mineral formulation T-AYU-HM Premium in sickle cell anemia patients. J Young Pharm., 2025; 17(2).
12. Desai AM, Desai HA, Desai RA, Merai AK, Desai C, Khan M, Paul A. An acute oral toxicity study of T-AYU-HM Premium tablet in rats. Int J Pharm Sci Res., 2020; 11(12): 6157-60. doi:10.13040/IJPSR.0975-8232.11(12).6157-60
13. Desai A. Antioxidant activity evaluation of T-AYU-HM Premium. World J Med Pharm Res., 2025; 11(3).